2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Value, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6031 Donor related logistical challenges in hematopoietic transplant: A comparative analysis of related and unrelated donors

Frederick Ian Lemaistre, MD, MPH, Kathryn Yarkony2, Alexander Joseph Ambinder, MD, MPH3, Christian Burris Gocke, MD, PhD4, Heather J. Symons, MD5, Amy DeZern, MD, MHS6, Kenneth R Cooke, MD7, Javier Meade8, Ravi Varadhan, PhD9, Richard John Jones, MD10
1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
2 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
3 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
4 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
5 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
6 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
7 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
8 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
9 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States
10 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, United States

Background: Mismatched donor platforms have expanded access to allogeneic blood and bone marrow transplantation (alloBMT), providing patients near universal access often with multiple viable donor options. Thus, identifying optimal donors has become increasingly important. Existing observational studies on the subject assess outcomes only among patients who successfully proceeded to alloBMT, leaving earlier, donor-related barriers, logistical challenges, and costs unexamined.

Methods: We conducted a retrospective analysis of patients with hematologic malignancies who underwent alloBMT with post-transplant cyclophosphamide (PTCy) at a single institution. We evaluated overall survival (OS) in all patients between 2018 and 2025 by donor type. We then assessed donor-related transplant delays or cancellations, as well as total transplant and graft charges by donor type in 374 consecutive patients transplanted between January 1, 2024, and December 31, 2025.

Results: In 1298 patients, OS did not differ by donor-type. Compared to related donors (RDs), unrelated donor (URD) transplants in 2024-2025 were more likely to experience a donor-related delay (26% vs 2.2 %, p<0.001). Both URDs (OR 14.3, 95% CI 5.08 – 49.6; p <0.001) and Black patients (OR 2.98, 95% CI 1.27-6.66; p = 0.010) had significantly increased odds of donor-related delays on univariable regression. Charges for URD transplants were significantly higher than RD ($184,036 vs $150,716 p <0.001), driven by graft acquisition charges.

Conclusions: Using PTCy, survival outcomes were comparable across donor types. Related donors were more likely to advance to a timely donation, reflecting higher availability, stronger personal commitment, and fewer logistical barriers compared with unrelated donors.

Frederick Ian Lemaistre, MD, MPH: No relevant conflicts of interest to declare.